Skip to Content

'
James W. Welsh, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2003 Dartmouth School of Medicine, Hanover, NH, MD, Medicine
1997 University of California, Davis, CA, BS, Genetics

Postgraduate Training

7/2004-6/2008 Clinical Residency, Radiation Oncology, The University of Arizona Health Sciences Center, Tucson, AZ
7/2003-6/2004 Clinical Internship, Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH

Board Certifications

7/2009 American Board of Radiology, Radiation Oncology, Recertification Date: 3/2014

Experience/Service

Academic Appointments

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2008-8/2014

Other Appointments/Responsibilities

Research Associate, Dartmouth Hitchcock Medical Center, Lebanon, NH, 7/2003-12/2003
Research Associate, Division of Molecular Oncology, Genentech, Inc, San Francisco, CA, 5/1997-8/1999
Research Assistant, University of California Davis Medical School, Davis, CA, 9/1996-4/1997

Consultantships

Scientific Advisor, Pfizer, Inc., New York, NY, 2013-present
Scientific Advisor, RefleXion Medical, San Francisco, CA, 2011-present
Scientific Advisor, Ventana Medical, Tucson, AZ, 2011-present

Institutional Committee Activities

Board Member, Center for Professional Development and Entrepreneurship Board of Advisors, 2013-present
Member, Medical Practice Committee, 2012-2014
Member, American Society of Radiation Oncology Research Evaluation, 2009-present

Honors and Awards

2016 ASTRO Abstract Award, Annual Meeting Scientific Program Committee of the American Society for Radiation Oncology
2012 Educational Grant, Hiroshima International Council for Health Care of the Radiation-Exposed (HICARE), Hiroshima International Council for Health Care
2009 Best of ASTRO Award, Media Feature, American Society of Radiation Oncology
2009 Honorarium, Texas Radiological Society
2009 Honorarium and Plaque, American College of Veterinary Radiation
2008 Honorarium, Chicago Multidisciplinary Symposium in Thoracic Oncology, American Society of Radiation Oncology
2007 Annual Meeting Travel Grant Award, American Society of Radiation Oncology
2007 Methods in Clinical Cancer Research Award, American Society of Clinical Oncology
2007 Roentgen Resident/Fellow Research Award, Radiological Society of North America
2007 Translational Research Symposium Travel Grant, American Society of Radiation Oncology
2006 Best of American Brachytherapy Society, American Brachytherapy Society
2006 Best of ASTRO Translational Research Symposium, American Society of Radiation Oncology
2006 European Organization for Research and Treatment of Cancer Research and Travel Award, SuperGen
2006 Excellence in Scientific Publishing, American Brachytherapy Society
2006 First Place Abstract, Los Angeles Radiological Society Annual Meeting
2006 International Conference of Translational Radiotherapy Travel Honorarium, Cytyc, Inc
2006 Translational Research Symposium Travel Grant, American Society of Radiation Oncology
2006 Travel Grant Award, American Brachytherapy Society
2005 Translational Research Symposium Travel Grant, American Society of Radiation Oncology

Professional Memberships

American Association for Cancer Research
Member, 2009-present
American Radium Society
Member, 2006-present
American Society of Clinical Oncology
Member, 2008-present
American Society of Radiation Oncology
Member, Research Evaluation Committee of the Science Council, 2012-present
Member, 2008-present
Radiation Therapy Oncology Group
Member, 2009-present
Radiological Society of North America
Member, 2009-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Cheedella KS, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welsh J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. In Press.
2. Shirvani S, Smith B, Welsh J. Lobectomy, sublobar resection, and stereotactic radiation for early-stage non-small cell lung cancer in the elderly. JAMA. In Press.
3. Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J 22(2):130-7, Mar-Apr, 3/2016. PMID: 27111909.
4. Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst 108(1), 1/2016. e-Pub 11/2015. PMCID: PMC4862407.
5. Li P, Wang X, Liu Z, Liu H, Xu T, Wang H, Gomez DR, Nguyen QN, Wang LE, Teng Y, Song Y, Komaki R, Welsh JW, Wei Q, Liao Z. Single nucleotide polymorphisms in CBLB, a regulator of T-cell response, predict radiation pneumonitis and outcomes after definitive radiotherapy for non-small-cell lung cancer. Clin Lung Cancer 7304(15):272-277, 11/2015.
6. Li P, Wang X, Liu Z, Liu H, Xu T, Wang H, Gomez DR, Nguyen QN, Wang LE, Teng Y, Song Y, Komaki R, Welsh JW, Wei Q, Liao Z. Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. Clin Lung Cancer. e-Pub 11/2015. PMID: 26732495.
7. Smith BD, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Shirvani SM. Cost-Effectiveness of Stereotactic Radiation, Sublobar Resection, and Lobectomy for Early Non-Small Cell Lung Cancers in Older Adults. J Geriatr Oncol 6(4):324-31, 7/2015. e-Pub 6/2015. PMCID: PMC4536110.
8. Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 92(2):317-24, 6/2015. PMCID: PMC4432249.
9. Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer 16(2):156-63, 3/2015. e-Pub 10/2014. PMID: 25467928.
10. Seyedin SN, Tang C, Welsh JW. Author's view: radiation and immunotherapy as systemic therapy for solid tumors. Oncoimmunology 4(3):e986402, 1/2015. e-Pub 1/2015. PMCID: PMC4404906.
11. Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DR. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys 91(1):149-56, 1/2015. e-Pub 10/2014. PMID: 25442335.
12. Cortez MA, Valdecanas D, Niknam S, Peltier HJ, Diao L, Giri U, Komaki R, Calin GA, Gomez DR, Chang JY, Heymach JV, Bader AG, Welsh JW. In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. Mol Ther Nucleic Acids 4:e270, 2015. e-Pub 12/2015. PMID: 26670277.
13. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-80, 2015. e-Pub 8/2015. PMCID: PMC4825325.
14. Welsh JW, Seyedin SN, Cortez MA, Maity A, Hahn SM. Galectin-1 and Immune Suppression during Radiotherapy. Clin Cancer Res 20(24):6230-2, 12/2014. e-Pub 10/2014. PMID: 25348514.
15. Selek U, Bölükbasi Y, Welsh JW, Topkan E. Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer. Balkan Med J 31(4):286-94, 12/2014. e-Pub 9/2014. PMCID: PMC4318398.
16. Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Smith BD. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg 149(12):1244-53, 12/2014. PMCID: PMC4401470.
17. Xu T, Liao Z, O'Reilly MS, Levy LB, Welsh JW, Wang LE, Lin SH, Komaki R, Liu Z, Wei Q, Gomez DR. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol 113(3):379-84, 12/2014. e-Pub 11/2014. PMID: 25466375.
18. Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, Pan HY, Chang JY, Komaki R, Cox JD, McAleer MF, Grosshans DR. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol 9(10):1554-60, 10/2014. PMCID: PMC4273574.
19. Yu WW, Zhu ZF, Fu XL, Zhao KL, Mao JF, Wu KL, Yang HJ, Fan M, Zhao S, Welsh J. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma : early results of a phase II study. Strahlenther Onkol 190(11):979-86, 10/2014. e-Pub 3/2014. PMID: 24609941.
20. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? Cancer Immunol Res 2(9):831-838, 9/2014. PMID: 25187273.
21. Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol 9(8):1202-1206, 8/2014. PMID: 25157774.
22. Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 89(5):1084-1091, 8/2014. e-Pub 7/2014. PMID: 25035212.
23. Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, Balter PA, Chang JY. Stereotactic ablative radiotherapy (SABR) using 70Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications. Radiother Oncol 112(2):256-61, 8/2014. e-Pub 8/2014. PMID: 25108807.
24. Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, Komaki R, Giri DK, Quini CC, Wolfe T, Peltier HJ, Bader AG, Heymach JV, Meyn RE, Welsh JW. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther 22(8):1494-1503, 8/2014. e-Pub 5/2014. PMCID: PMC4435581.
25. Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. Cancer 120(6):790-798, 3/2014. e-Pub 12/2013. PMCID: PMC3947683.
26. Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors Associated with Local-Regional Failure After Definitive Chemoradiation for Locally Advanced Esophageal Cancer. Ann Surg Oncol 21(1):306-314, 1/2014. e-Pub 11/2013. PMID: 24197760.
27. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241, 2014. e-Pub 10/2014. PMCID: PMC4212319.
28. Yang J, Amini A, Williamson R, Zhang L, Zhang Y, Komaki R, Liao Z, Cox J, Welsh JW, Court L, Dong L. Automatic contouring of brachial plexus using a multi-atlas approach for lung cancer radiotherapy. Pract Radiat Oncol 3(4):e139-e147, 10/2013. PMCID: PMC3833708.
29. Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, Banchs J, Komaki R, Welsh JW. Cardiac (18)F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol 109(1):82-88, 10/2013. e-Pub 9/2013. PMID: 24016676.
30. Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh JW, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):139-147, 9/2013. PMID: 23920393.
31. Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, Roth JA, Swisher SG. Stereotactic ablative radiotherapy: a potentially curable approach to early-stage multiple primary lung cancer. Cancer 119(18):3402-3410, 9/2013. e-Pub 6/2013. PMCID: PMC3775964.
32. Francis AM, Sepesi B, Correa AM, Blum MA, Erasmus JJ, Lee JH, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Welsh JW, Swisher SG, Hofstetter WL, University of Texas MD Anderson Esophageal Cancer Group. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg 258(3):500-507, 9/2013. PMID: 24022442.
33. Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg 17(8):1359-1369, 8/2013. e-Pub 5/2013. PMID: 23715646.
34. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-1009, 6/2013. e-Pub 9/2012. PMID: 22950385.
35. Benveniste MF, Welsh JW, Godoy MC, Betancourt SL, Mawlawi OR, Munden RF. New era of radiotherapy: an update in radiation-induced lung disease. Clin Radiol 68(6):e275-e290, 6/2013. e-Pub 3/2013. PMID: 23473474.
36. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312-1319, 5/2013. e-Pub 1/2013. PMCID: PMC3629895.
37. Bhardwaj V, Cascone T, Cortez MA, Amini A, Evans J, Komaki RU, Heymach JV, Welsh JW. Modulation of c-met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer 119(10):1768-1775, 5/2013. e-Pub 2/2013. PMCID: PMC3648606.
38. Evans JD, Gomez DR, Amini A, Rebueno N, Allen PK, Martel MK, Rineer JM, Ang KK, McAvoy S, Cox JD, Komaki R, Welsh JW. Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol 106(3):327-332, 3/2013. e-Pub 2/2013. PMCID: PMC3921976.
39. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. J Clin Oncol 31(7):895-902, 3/2013. e-Pub 1/2013. PMCID: PMC3577951.
40. Gomez DR, Hong DS, Allen PK, Welsh JW, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DC. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol 8(2):238-245, 2/2013. e-Pub 12/2012. PMID: 23247629.
41. Welsh JW, Amini A, Ciura K, Nguyen N, Palmer M, Soh H, Allen PK, Paolini M, Liao Z, Bluett J, Mohan R, Gomez D, Cox JD, Komaki R, Chang JY. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim 38(4):442-7, 2013. PMCID: PMC4086145.
42. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh JW, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer 48(18):3396-3404, 12/2012. e-Pub 7/2012. PMID: 22853875.
43. Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 84(5):1060-1070, 12/2012. e-Pub 9/2012. PMCID: PMC3776428.
44. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh JW, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 23(10):2638-2642, 10/2012. e-Pub 7/2012. PMCID: PMC3457750.
45. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh JW, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus 25(7):614-622, 9/2012. e-Pub 12/2011. PMID: 22150920.
46. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh JW, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2(9):798-811, 9/2012. e-Pub 9/2012. PMID: 22961666.
47. Bhardwaj V, Zhan Y, Cortez MA, Ang KK, Molkentine D, Munshi A, Raju U, Komaki R, Heymach JV, Welsh J. c-MET inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol 7(8):1211-1217, 8/2012. e-Pub 5/2012. PMCID: PMC3399033.
48. Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, Ajani JA, Welsh JW. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys 83(2):e231-e239, 6/2012. e-Pub 3/2012. PMID: 22436793.
49. Welsh JW, Settle S, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118(10):2632-2640, 5/2012. e-Pub 10/2011. PMID: 22565611.
50. Yin M, Liao Z, Yuan X, Guan X, O'Reilly MS, Welsh JW, Wang LE, Wei Q. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 103(5):945-950, 5/2012. e-Pub 3/2012. PMCID: PMC3337362.
51. Amini A, Yang J, Williamson R, McBurney ML, Erasmus J, Allen PK, Karhade M, Komaki R, Liao Z, Gomez D, Cox JD, Dong L, Welsh JW. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys 82(3):e391, 3/2012. PMID: 22284035.
52. Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, Marom EM, Welsh JW, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg 143(2):412-420, 2/2012. e-Pub 12/2011. PMID: 22172216.
53. Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh JW, Marom EM, Swisher SG, Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg 93(1):207-212; discussion 212-213, 1/2012. e-Pub 10/2011. PMID: 21962263.
54. Welsh JW, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 82(1):468-474, 1/2012. e-Pub 12/2010. PMID: 21123005.
55. Cortez MA, Welsh JW, Calin GA. Circulating microRNAs as non-invasive biomarkers in breast cancer. Recent Results Cancer Res 195:151-61, 2012. PMCID: PMC3855311.
56. Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh JW, Mehran RJ, Roth JA, Swisher SG. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 7(152):1-10, 2012. e-Pub 9/2012. PMCID: PMC3444889.
57. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology 82(2):108-113, 2012. e-Pub 2/2012. PMID: 22328056.
58. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh JW, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology 83(5):300-304, 2012. e-Pub 9/2012. PMID: 22964903.
59. Welsh JW, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, Ajani JA, Cox JD. Intensity-modulated proton therapy further reduces normal-tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 81(5):1336-1342, 12/2011. e-Pub 4/2011. PMID: 21470796.
60. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4823-4833, 11/2011. e-Pub 3/2011. PMCID: PMC3144261.
61. Welsh JW, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R, Chang JY. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 81(1):91-96, 9/2011. PMID: 20542388.
62. Ajani JA, Blum MA, Welsh JW, Hofstetter WL, Swisher SG. Celebrate or calibrate? We say calibrate. J Clin Oncol 29(19):2732-2733, 7/2011. e-Pub 5/2011. PMID: 21606421.
63. Welsh JW, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 13(3):157-167, 6/2011. PMID: 21365188.
64. Turner LM, Howard JA, Dehghanpour P, Barrett RD, Rebueno N, Palmer M, Vedam S, Klopp A, Komaki R, Welsh JW. Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies. Med Dosim 36(4):383-388, 2011. e-Pub 12/2010. PMID: 21144734.
65. Nguyen NP, Bishop M, Borok TJ, Welsh JW, Hamilton R, Cohen D, Nguyen LM, Vincent VH. Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. Anticancer Res 30(3):953-961, 3/2010. PMID: 20393019.
66. Welsh JW, Ellsworth RK, Kumar R, Fjerstad K, Martinez J, Nagel RB, Eschbacher J, Stea B. Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 74(4):1251-1255, 7/2009. PMID: 19545791.
67. Olsen CC, Welsh JW, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE, Schefter TE. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 73(5):1414-1424, 4/2009. e-Pub 11/2008. PMID: 18990508.
68. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B. The c-MET receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 4(69):69, 2009. e-Pub 12/2009. PMCID: PMC2806296.
69. Nguyen NP, Garland L, Welsh JW, Hamilton R, Cohen D, Vinh-Hung V. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev 34(8):719-727, 12/2008. e-Pub 7/2008. PMID: 18657910.
70. Ellsworth R, Welsh JW, Mahadevan D, Bearrs D, Hsieh D, Fjerstad HK, Marsella M, Sanan A, Badrudoja M, Stea B. The radiosensitizing effects of a novel tyrosine kinase inhibitor, Mp470, in glioblastoma multiforme stem cells. Int J Radiat Oncol Biol Phys 72(1):S714-S715, 9/2008.
71. Nguyen NP, Vos P, Lee H, Borok TL, Karlsson U, Martinez T, Welsh JW, Cohen D, Hamilton R, Nguyen N, Nguyen LM, Vinh-Hung V. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer. Oncology 75(3-4):186-191, 2008. e-Pub 10/2008. PMID: 18841033.
72. Welsh JW, Abhay S, Gabayan A, Green SB, Lustig R, Burri S, Kwong E, Baldassarre S. GliaSite radiotherapy boost as part of initial treatment of malignant gliomas: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 68(1):159-165, 2007.
73. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ. WISP-1 is a Wnt-1 and beta-catenin-responsive oncogene. Genes Dev 14(5):585-595, 3/2000. PMCID: PMC316421.
74. Pennica D, Swanson T, Welsh JW, Roy M, Lawrence D, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem M, Finley G, Quirke P, Goddard AD, Hillan KJ, Gurney AL, Botstein D, Levine AJ. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 95(25):14717-14722, 12/1998. PMCID: PMC24515.

Editorials

1. Welsh JW, McGovern SL, Wefel JS, Komaki R, Brown PD, Soh HE. Reply to V.R. Bhatt et al and M.C. Chamberlain. J Clin Oncol 31(25):3165-3166, 9/2013. e-Pub 7/2013. PMID: 23943829.
Other Articles
1. Welsh JW. Book review: Textbook of lung cancer, 2nd edition. Int J Radiat Oncol Biol Phys 73(4):1283, 3/2009.

Abstracts

1. Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, Kelnar K, Martin D, Komaki R, Gomez DR, Krishnan S, Calin GA, Bader AG, Welsh JW. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst 108(1). e-Pub 11/2015.
2. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-980, 8/2015.
3. Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small Cell lung cancer. Int J Radiat Oncol Biol Phys 92(2):317-324, 6/2015.
4. Seyedin SN, Tang C, Welsh JW. Author's view: radiation and immunotherapy as systemic therapy for solid tumors. OncoImmunology 4(3) (#986402), http://www.tandfonline.com, 3/2015. e-Pub 3/2015.
5. Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer 16(2):156-63, 3/2015. e-Pub 10/2014. PMID: 25467928.
6. Nguyen Q, Tang C, Chance WW, Balter P, Welsh JW, Gomez DR, Komaki RU, Liao Z, Chang JY, Mehran RJ. Outcomes, Patterns of Failures and Toxicity for patients diagnosed with Pulmonary Metastases treated with Stereotactic Body Ablative Radiotherapy (SABR). ASTRO 2015, 2/2015.
7. Tang Chad, Naing Aung, De Groot Patricia, Chang Joe, Massarelli Erminia, Parkhurst Kristin L., Erdman Denise, Barrientes Sylvia, Fok Jansina, Subbiah Vivek, Fu Siqing, Tsimberidou Apostolia, Karp Daniel, Gomez Daniel, Heymach John V., Hahn Stephen M., Komaki Ritsuko, Hong David, Welsh James W. Phase 1 Study of ipilimumab and Sterotactic Radiation Targeting Liver or Lung Lesions in Patients with Advanced Malignancies. Astro Abstract 2015, 2015, 2015.
8. Chance WW, Nguyen Q, Mehran R, Welsh JW, Gomez DR, Balter P, Komaki R, Liao Z, Chang J. Stereotactic ablative radiotherapy for treatment of adrenal gland metastasis: toxicity, patterns of failure, and factors impacting outtcomes. Proceedings of 2015 ASTRO Annual Meeting, 2015.
9. Gavini H, Sheu-Woc W, Singh A, Ross WA, Ajani JA, Bhutani MS, Weston BR, Hofstetter WL, Davila ML, Raju GS, Welsh J, Lee J. Is a repeat endoscopy (EGD) necessary when referred for staging of newly diagnosed esophageal cancer? : A comparison of cancer specialty institution (CSI) with other institutions (OSF). Gastroenterol 146(5):S511-S512, 5/2014.
10. Cortez MA, Yang C, Byers L, Diao L, Allen T, Giri U, Wang J, Welsh J, Heymach J. Reciprocal regulation of MYC and LKB1 modulates cell survival and differentiation in lung cancer. Proceedings of the American Association for Cancer Research (#5220), 4/2014.
11. Komaki R, Allen P, Wei X, Gomez D, Heymach JV, Welsh J, O'Reilly M, Takahashi O, Lin SH, Cox JD. Duration of thoracic radiotherapy with concurrent chemotherapy is important for outcome of patients with limited-stage small cell lung cancer (L-SCLC). J Thoracic Oncol 8(2):S336, 11/2013.
12. Chang J, Liu YH, Zhu ZH, Welsh J, Gomez D, Komaki R, Roth JA, Swisher SG,. Stereotactic ablative radiotherapy: a potentially curable approach to multiple primary lung cancer. J Thoracic Oncol 8(2):S1133 (#1454), 11/2013.
13. Komaki R, Allen P, Wei X, Blumenschein G, Tang XM, Lee J, Welsh J, Wistuba II, Liu DD, Hong WK. Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study. J Thoracic Oncol 8(2):S136, 11/2013.
14. Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, Banchs J, Komaki R, Welsh J. Cardiac isodose distributions and increases in focal 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic ablative radiotherapy. Int J Radiat Oncol Biol Phys 87(2):S645, 10/2013.
15. Xu T, Gomez D, O’Reilly M, Levy LB, Welsh J, Lin SH, Komaki R, Liu Z, Wei Q, Liao Z. Circulating miR-155 predicts for acute esophageal toxicity in patients with non-small cell lung cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 87(2):S93-S94, 10/2013.
16. Komaki R, Allen P, Wei X, Gomez D, Heymach J, Welsh J, O’Reilly M, Lin S, Cox JD. Duration of thoracic radiotherapy with concurrent chemotherapy is important for the outcome of patients with limited stage small cell lung cancer (LS-SCLC). Int J Radiat Oncol Biol Phys 87(2):S537, 10/2013.
17. Soh HE, Bhardwaj V, Cortez MA, Allen PK, Heymach J, Li X, Meyn R, Xia D, Gomez DR, Skinner HJ, Liao Z, Komaki R, Welsh J. Elevated serum HGF is associated with radioresistance and local recurrence in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 87(2):S652, 10/2013.
18. Naik NS, Swanick CW, Wei C, Liao Z, Welsh JW, Komaki R, Chang JY, O’Reilly MS, Gomez D, Lin SH. High local failure rates despite dose escalation may support the metastatic self-seeding phenomena in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 87(2):S519, 10/2013.
19. Wei X, Allen PK, Gomez D, Kotamarti J, Heymach J, Welsh J, O’Reilly M, Lin SH, Cox JD, Komaki R. Improved 5-year disease free-survival and distant metastasis-free survival for patients with limited-stage small cell lung cancer who had 18F-fluorodeoxyglucose positron emission tomography (PET) or PET/CT before chemoradiation therapy. Int J Radiat Oncol Biol Phys 87(2):S536, 10/2013.
20. Swanick CW, Naik NS, Liao Z, Welsh J, Komaki R, Chang JY, O'Reilly M, Lin SH, Gomez D. Toxicity and local control with intensity-modulated radiation therapy (IMRT) using a simultaneous integrated boost (SIB) hypofractionated approach for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 87(2):S508, 10/2013.
21. Singh A, Ladha HS, Bhattacharya A, Welsh J, Qiao W, Krishna SG, Ross WA, Bhutani MS, Ajani JA, Hofstetter WL, Swisher SG, Lee JH. Is dilation necessary to complete EUS staging for esophageal cancer?. Gastrointest Endosc 77(5):AB361, 5/2013.
22. Welsh J, Likacheva A, Byers LA, Bhardwaj V, Diao L, Wang J, Ang KK, Romaki R, Kim E, Heymach JV. Implications of KRAS mutations on outcomes in non-small cell lung cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 84(35):S70 (#172), 10/2012.
23. Wang H, Gomez DR, Komaki R, Welsh J, O’Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Liao Z. Improved survival outcomes in non-small cell lung cancer patients with incidental concurrent use of beta-blockers and definitive radiation therapy. Int J Radiat Oncol Biol Phys 84(35):S587 (#2901), 10/2012.
24. Juloori A, Shirvani SM, Allen PK, Komaki R, Liao Z, Welsh J, Gomez DR, Heymach JV, Chang JY. Limited-stage small cell lung cancer in the contemporary period: impact of new technologies on outcomes. Int J Radiat Oncol Biol Phys 84(35):S592 (#2994), 10/2012.
25. Gomez DR, Liao K, Chang JY, Liao Z, Shirvani SM, Komaki R, Welsh J, Swisher SG, Heymach JV, Smith BD. Patient selection for treatment modality in stage III non-small cell lung cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 84(35):S540 (#2859), 10/2012.
26. Shirvani SM, Juloori A, Gomez DR, Allen PK, Komaki R, O’Reilly MS, Liao Z, Welsh J, Papdimitrakopoulou V, Chang JY. Patterns of failure for limited-stage small cell lung cancer following definitive radiation in the modern era. Int J Radiat Oncol Biol Phys 84(35):S595 (#3004), 10/2012.
27. Komaki R, Allen P, We Xi, Blumenschein G, Wistuba I, Lee J, Welsh J, O’Reilly M, Tang X, Hong W. Phase II trial of erotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer has shown a favorable response profile. Int J Radiat Oncol Biol Phys 84(35):S68 (#169), 10/2012.
28. Fakhreddine M, Liao Z, Zhuang Y, Bhardwaj V, Tucker S, Skinner H, Heymach J, Gomez D, Komaki R, Welsh J. Poor glycemic control during radiochemotherapy contributes to reduced local control and overall survival in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(35):S69 (#171), 10/2012.
29. Zhuang Y, Gomez DR, Komaki R, O’Reilly MS, Welsh J, Lin SH, Chang JY, Jeter M, Liao Z. Prognostic factors for overall survival in stage IIIA/IIIB non-small cell lung cancer after definitive (chemo)radiation therapy. Int J Radiat Oncol Biol Phys 84(35):S591 (#2993), 10/2012.
30. McAvoy S, Komaki R, Allen P, Rineer J, Liao Z, Chang J, Welsh J, Palmer M, Cox J, Gomez D. Reirradiation with proton beam therapy or intensity modulated radiation therapy for non-small cell lung cancer: an institutional experience. Int J Radiat Oncol Biol Phys 84(35):S608 (#3037), 10/2012.
31. Gomez DR, Liao K, CHang JY, Liao Z, Shirvani SM, Komaki R, Welsh J, Heymach JV, Swisher SG, Smith BD. Treatment modality and other prognostic factors for overall survival in stage III non-small cell lung cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 84(35):S540 (#2858), 10/2012.
32. Juloori A, Shirvani S, Allen P, Komaki R, Liao Z, Welsh J, Gomez D, Heymach JV, Chang JY. Limited-stage small cell lung cancer in the contemporary period: impact of new technologies on outcomes. J Thorac Oncol 7(15):S329 (#1127), 9/2012.
33. Skinner H, McCurdy M, Echeverria A, Lin S, Welsh J, O'Reilly MO, Hofstetter W, Ajani J, Komaki R, Guerrero T. Metformin use is associated with improved response to neoadjuvant chemoradiation in esophageal adenocarcinoma. J Thorac Oncol 7(15):S240 (#177), 9/2012.
34. Shirvani SM, Juloori A, Gomez D, Allen P, Komaki R, O'Reilly MO, Liao Z, Welsh J, Papadimitrakopoulou V, Chang JY. Patterns of failure for limited-stage small cell lung cancer following definitive radiotherapy in the modern era. J Thorac Oncol 7(15):S279 (#282), 9/2012.
35. Komaki R, Allen P, Wei X, Blumenschein G, Wistuba I, Lee J, Welsh J, O'Reilly M, Tang X, Hong W. Phase II trial of erotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer has shown a favorable response profile. J Thorac Oncol 7(15):S279 (#281), 9/2012.
36. Komaki R, Allen P, Wei X, Gomez D, Fossella F, Heymach J, Welsh J, O’Reilly M, Lin S, Cox JD. Thoracic radiotherapy within 6 weeks with concurrent chemotherapy improved outcome of patients with limited stage small cell lung cancer (LS-SCLC). J Thorac Oncol 7(15):S217 (#114), 9/2012.
37. Blum M, Hayashi Y, Xiao L, Suzuki A, Sabloff B, Maru D, Taketa T, Welsh JW, Lin S, Lee J, Bhutani M, Weston B, Hofstetter W, Swisher S, Ajani J. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with esophageal cancer (EC). J Clin Oncol 30(suppl):abstr e14547, 6/2012.
38. Cheedella S, Suzuki A, Correa A, Hofstetter W, Mehran R, Rice D, Maru D, Vaporciyan A, Taketa T, Blum M, Welsh J, Lin S, Lee J, Bhutani M, Weston B, Walsh G, Swisher S, Ajani J. Association of clinical complete response (cCR) after preoperative chemoradiation and pathological complete response (pathCR) in patients with gastroesophageal cancer (GEC) and indispensability of trimodality therapy (TMT). J Clin Oncol 30(suppl):abstr 4086, 6/2012.
39. Shirvani S, Jiang J, Chang J, Gomez D, Welsh J, Swisher S, Buchholz T, Smith B. Comparative effectiveness of five treatment strategies for early-stage non-small cell lung cancer in the elderly. J Clin Oncol 30(suppl):abstr 7062, 6/2012.
40. Suzuki A, Xiao L, Taketa T, Blum M, Welsh J, Lin S, Weston B, Lee J, Bhutani M, Rice D, Mehran R, Maru, Erasmus J, Hofstetter W, Swisher S, Ajani J. Customization of treatment for patients with esophageal adenocarcinoma (EAC) who achieve clinical complete response (cCR) after chemoradiation using initial standardized uptake value (iSUV) of 18f-fluorodeoxyglucose PET. J Clin Oncol 30(suppl):abstr 4069, 6/2012.
41. Amini A, Welsh J, Allen P, Xiao L, Suzuki A, Hayashi Y, Blum M, Hofstetter W, Liao Z, Lee J, Bhutani M, Komaki R. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. J Clin Oncol 30(suppl):abstr e14669, 6/2012.
42. Byers L, Nilsson M, Masrorpour F, Wang J, Diao L, Bhardwaj V, Welsh J, Girard L, Coombes K, Weinstein J, Lippman L, Glisson B, Minna J, Heymach J. Investigation of PARP1 as a therapeutic target in small cell lung cancer. J Clin Oncol 30(suppl):abstr 7096, 6/2012.
43. Taketa T, Correa A, Suzuki A, Blum M, Lee J, Welsh J, Lin S, Maru D, Erasmus J, Bhutani M, Weston B, Rice D, Swisher S, Hofstetter W, Ajani J. Outcome of 58 trimodality-eligible esophagogastric cancer (EC) patients who achieved clinical complete response (cCR) after preoperative chemoradiation but then declined surgery. J Clin Oncol 30(suppl):abstr 4078, 6/2012.
44. Bhardwaj V, Likhacheva A, Byers L, Komaki R, Kim E, Heymach J, Welsh J. Establishing role of KRAS mutation on NSCLC radio-sensitivity. Proceedings of the American Association for Cancer Research Annual Meeting (#3454), 4/2012.
45. Cortez M, Bhardwaj V, Zhan Y, Byers L, Calin G, Heymach J, Welsh J. Mir-200c overexpression radiosensitizes lung cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting (#1099), 4/2012.
46. Benveniste M, Betancourt S, Godoy M, Mawlawi O, Welsh J, Munden R. New era of radiotherapy: an update in radiation-induced lung disease. Proceedings of the Scientific Assembly and Annual Meeting of the Radiological Society of North America, 11/2011.
47. Gomez DR, Amin MV, Crawford C, Welsh J, Chang JY, Zhu XR, Liao Z, Komaki R, Cox JD, Mohan R. A comparison of strategies to account for bowel filling in patients treated with proton therapy for locally advanced distal esophageal cancer: a planning study. Int J Radiat Oncol Biol Phys 81(2s):S883, 10/2011.
48. Amini A, Welsh JW, Yang J, McBurney ML, Williamson MT, Karhade M, Allen P, Erasmus J, Dong L, Liao Z. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys 81(2s):S110-S111, 10/2011.
49. Ciura KT, Welsh J, Nguyen N, Palmer M, Paolini M, Bluett J, Mohan R, Gomex D, Cox JD, Chang J. Evaluating stereotactic body radiotherapy with protons to reduce chect wall dose in the treatment of lung cancer. Int J Radiat Oncol Biol Phys 81(2s):S87, 10/2011.
50. Welsh J, Kim E, Amin A, Allen P, Chang J, Komaki R, Nguyen N, Holt J, Erdman D, Stea B. Phase II safety data of erlotinib with concurrent whole-brain radiation therapy for patients with brain metastasis from non-small cell lung cancer. Int J Radiat Oncol Biol Phys 81(2s):S136, 10/2011.
51. Komaki R, Blumenschein GR, Wistuba II, Lee J, Allen PK, Wei X, Welsh J, O'Reilly MS, X Tang, Hong W. The phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer has shown a favorable response profile. Int J Radiat Oncol Biol Phys 81(2s):S591-S592, 10/2011.
52. Welsh J, Amini A, Kim ES, Allen P, Chang JY, Garland LL, Holt J, Erdman D, Komaki R, Stea B. Phase II study of erlotinib with concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. J Clin Oncol 29(suppl):abstr 2031, 6/2011.
53. Komaki R, Blumenschein GR, Wistuba II, Lee JJ, Allen P, Wei X, Welsh J, O'Reilly M, Herbst S, Tang X, Meyn RLiu D, Hong WK. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. J Clin Oncol 29(suppl):abstr 7020, 6/2011.
54. Suzuki A, Xiao L, Hayashi Y, Welsh J, Lin SH, Maru D, Hofstetter WL, Mehran RJ, Lee JH, Bhutani MS, Macapinlac HA, Liao ZX, Ajani JA. Prognostic significance of post-treatment standardized uptake value (pSUV) of positron emission tomography (PET) to predict overall survival (OS) and relapse-free survival (RFS) in patients with esophageal or gastroesophageal cancer treated with definitive chemoradiotherapy. J Clin Oncol 29(suppl):abstr 4055, 6/2011.
55. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Suzuki A, Lee H, Bhutani MS, Lin SH, Welsh J, Maru D, Swisher S, Ajani JA. The association between body mass index and baseline clinical stage of esophageal carcinoma. J Clin Oncol 29(suppl):abstr 4090, 6/2011.
56. Ajani JA, Wang X, Hayashi Y, Maru D, Welsh J,Hofstetter WL, Lee JH, Bhutani MS, Suzuki A, Berry DA, Izzo J. Validated biomarker signatures that predict pathologic response to preoperative chemoradiation therapy (CTRT) with high specificity and desirable sensitivity levels in patients with esophageal cancer (EC). J Clin Oncol 29(suppl):abstr 4027, 6/2011.
57. Welsh J, Riley B, Palmer MB, Amin MV, Komaki R, Gomez D, Liao Z, Hofstetter WL, Ajani A, Cox JD. Intensity-modulated proton therapy allows dose escalation and normal-tissue sparing in locally advanced distal esophageal tumors. Int J Radiat Oncol Biol Phys 78(3s):S808, 11/2010.
58. Likhacheva A, Thomas J, Kim E, Allen P, Komaki R, Cox J, Herbst R, Welsh J. Predictive implications of KRAS and EGFR gene mutation in non-small cell lung cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 78(3s):S128-129, 11/2010.
59. Welsh J, Zhan Y, Likhacheva A, Komaki R. Radiation-induced c-MET expression sensitizes lung cancer cells to c-MET antagonists. Eur J Cancer 8(7):162 (#508), 11/2010.
60. Rebueno NC, Welsh JW. Exploring the feasibility of dose escalation with IMRT and the effects on normal tissue structures for thoracic malignancies. Int J Radiat Oncol Biol Phys 75(3s):S458, 11/2009.
61. Gao S, Chang JY, Welsh J, Komaki R, Balter P. Influence of the couch and immobilization device used during stereotactic body radiotherapy on skin dose. Int J Radiat Oncol Biol Phys 75(3s):S682, 11/2009.
62. Palmer MB, Vedam S, Komaki R, Welsh J. Intensity modulated radiation therapy (IMRT) benchmarks for thoracic malignancies. Int J Radiat Oncol Biol Phys 75(3s):S476, 11/2009.
63. Welsh JW, Thomas J, Wei X, Allen P, Mitchell K, Gao S, Komaki R, Chang J. Skin toxicity and pain in patients treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 75(3s):S61, 11/2009.
64. Welsh JW, Ellsworth R, Mahadevan D, Bearss D, Komaki R, Stea B. A c-MET receptor tyrosine kinase inhibitor offers increased radiosensitization in NSCLC after pretreatment with erlotinib. J Thorac Oncol 4(9, s1):S957 (#P3.241), 9/2009.
65. Takahashi O, Komaki R, Smith P, Ryan A, Jurgensmeier J, Welsh JW, Jacoby JJ, Hosho K, Korshunova M, Erez B, Herbst R, O'Reilly M. MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib. J Thorac Oncol 4(9, s1):S593 (#PD13.3.1), 9/2009.
66. Ellsworth R, Welsh JW, Mahadevan D, Bearrs D, Hsieh D, Fjerstad K, Marsella M, Sanan A, Badrudojja M, Stea B. The radiosensitizing effects of a novel tyrosine kinase inhibitor, MP470 in glioblastoma multiforme stem cells. Int J Radiat Oncol Biol Phys 72(1s):S714-S715, 9/2008.
67. Ellsworth R, Welsh JW, Kumar R, Fjerstad K, Green S, Nagle R, Stea B. CD133 expression before and after radiation in glioblastoma multiforme. Proceedings of the American Association for Cancer Research Annual Meeting (#1010), 4/2008.
68. Kumar R, Welsh JW, Nagle RB, Green S, Stea BD. Association between Rad-51 levels and survival in patients with glioblastoma multiforme treated with radiation therapy. Int J Radiat Oncol Biol Phys 69(3s):S63-S64, 11/2007.
69. Schefter TE, Welsh JW, Gaspar L, Kavanagh B. Normal liver V30% and mean liver dose predicts the maximum normal liver volume reduction after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 69(3s):S596, 11/2007.
70. Welsh JW, Mahadevan D, Bearss D, Stea B. Sensitization of a glioblastoma multiform (GBM) cell line by MP470: a novel c-MET antagonist. Int J Radiat Oncol Biol Phys 69(3s):S100, 11/2007.
71. Welsh JW, Mahadevan D, Dougherty G, Stea B. A c-MET receptor tyrosine kinase inhibitor radiosensitizes glioblastoma cells by reducing dsDNA repair, mediated through decreased Rad-51. Proceedings of the Annual Meeting of the American Radium Society, 5/2007.
72. Welsh JW, Garland L, Stea BD, Philip-Norton R. A phase II study to determine the efficacy of tarceva (erlotinib hydrochloride) with concurrent whole brain radiation therapy (WBRT) in patients with brain metastases from non-small cell lung cancer. J Thorac Oncol 2(8):S763, 2007.
73. Welsh JW, Mahadevan D, Dougherty G, Stea B. c-MET inhibition radiosensitizes melanoma by inhibiting double strand DNA repair. Int J Radiat Oncol Biol Phys 66(3s):S557-S558, 11/2006.
74. Watchman C, Hamilton R, Welsh JW. Implanted marker movements during prostate IMRT. Proceedings of the American Association of Physicists in Medicine Annual Meeting (#5897), 7/2006.
75. Welsh JW, Gabayan A, Sanan A, Stea B. GliaSite radiotherapy boost as part of initial treatment of malignant gliomas: A multi-institutional analysis. Brachytherapy 5(2):78-79, 4/2006.
76. Welsh JW, Gabayan A, Sanan A, Green S, Hass M, Burri S, Bishop M, Stea B. GliaSite radiotherapy boost as part of initial treatment of malignant gliomas: a multi-institutional analysis. Radiother Oncol 78(s1):S89-S90, 3/2006.

Book Chapters

1. Bhardwaj V, Cortez A, Fakhreddine M, Welsh J. Biologic principles of radiosensitization. In: Cancer Nanotechnology: Principles and Applications in Radiation Oncology. Ed(s) SH Cho, S Krishnan. Taylor and Francis Books, Inc: Boca Raton, FL, 15-24, 2013. ISBN: 9781439878750.
2. Lin S, Welsh J. Advanced-stage (III-IV) non-small cell lung cancer. In: Radiation Oncology: A Question-Based Review. Ed(s) Hristov B, Christodouleas J, Lin S. Lippincott Williams & Wilkins, 209-221, 2010.

Manuals, Teaching Aids, Other Teaching Publications

1. Laino C, Welsh J. Stereotactic body radiation therapy called new standard of care for inoperable early lung cancer. 31, 24. Oncology Times, 51-52, 12/2009.

Grant & Contract Support

Title: Using CAR-T and NK cells engineered to deliver IL-12 to expand T cells primed by radiation-induced antigens
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2016 - 3/31/2021
 
Title: BlockingTGF-β to reduce radiation pneumonitis and enhance abscopal responses in non-small cell lung cancer
Funding Source: The University of Texas MD Anderson Cancer Center
Role: Principal Investigator
Duration: 7/1/2015 - 6/30/2017
 
Title: Phase I/II Trial of MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients with NSCLC
Funding Source: Merck
Role: Principal Investigator
Duration: 5/1/2015 - 4/30/2018
 
Title: Phase l Trial of MD-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer
Funding Source: Merck
Role: Principal Investigator
Duration: 5/1/2015 - 4/30/2017
 
Title: Combining Radiation and the Immunomodulatery IDO inhibitor INCB024360 to Treat Lung Cancer
Funding Source: Incyte
Role: Principal Investigator
Duration: 5/1/2015 - 4/30/2017
 
Title: Combining radiotherapy with CSF-1R blockage to enhance anti-tumor activity in solid tumors
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2015 - 3/31/2017
 
Title: Using Radiation plus anti-PD1 immunotherapy to improve CAR T cell targeting of solid tumors
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2015 - 3/31/2017
 
Title: Using radiation plus anti-PD1 immunotherapy to improve CAR+ T-cell targeting of solid tumors
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 3/1/2015 - 2/28/2018
 
Title: Combining anti-OX40 Agonist Antibody Immunotherapy plus Radiotherapy to Overcome Metastatic Lung Cancer
Funding Source: GlaxoSmithKline (GSK)
Role: Principal Investigator
Duration: 11/1/2014 - 5/30/2016
 
Title: Targeting tumor-associated macrophages with anti-CSF1R in KRAS mutant tumors to overcome radioresistance in lung cancer
Funding Source: Lung Cancer Research Foundation
Role: Principal Investigator
Duration: 10/1/2014 - 9/30/2015
 
Title: Treatment of Metastatic Lung Cancer with Radiotherapy plus OX40 Immunotherapy
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2014 - 8/31/2016
 
Title: Southwest Early Clinical Trials (SECT) Consortium
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Funda Meric-Bernstam
Duration: 3/14/2014 - 2/28/2019
 
Title: Assessing the therapeutic effectiveness of miR-34a to overcome resistance to radiation
Funding Source: Doctors Cancer Foundation
Role: Principal Investigator
Duration: 7/1/2013 - 6/30/2015
 
Title: Evaluating miR34a as a radiation sensitizer for the treatment of lung cancer
Funding Source: Family of Mr. M. Adnan Hamed
Role: Principal Investigator
Duration: 5/1/2012 - present
 
Title: Evaluating modulation of c-Met antagonists as a radiation sensitizer for the treatment of lung cancer
Funding Source: Family of Mr. M. Adnan Hamed
Role: Principal Investigator
Duration: 7/1/2009 - present

Last updated: 5/22/2016